USA – Center for Drug Evaluation and Research – Office of Pharmaceutical Quality: Publication of the 2023 Annual Report
The FDA’s Office of Pharmaceutical Quality published its 2023 Annual report detailing its strategic priorities.
The Office of Pharmaceutical Quality’s (OPQ) mission is to assure that quality medicines are available for the American public. OPQ integrates assessment, inspection, surveillance, policy, and research activities to strengthen pharmaceutical quality on a global scale. OPQ supports “One Quality Voice,” creating a uniform drug quality program across all sites of manufacture — domestic or foreign — and across all human drug product areas including new drugs and biologics, generics, biosimilars, and also over-the-counter drugs and compounded drug products. OPQ also encourages the adoption of emerging technologies to enhance pharmaceutical quality and potentially reinvigorate the pharmaceutical manufacturing sector.
More information on the FDA Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (4 octobre 2024). USA – Center for Drug Evaluation and Research – Office of Pharmaceutical Quality: Publication of the 2023 Annual Report. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/12f6r





